Galectins in the Pathogenesis of Cerebrovascular Accidents: An Overview.

• Authors: William F Abel, University of South Carolina; Christopher Ronald Funk, Emory University; Anna Blenda, Emory University
• Journal Title: Journal of Experimental Neuroscience
• Volume: Volume 13
• Publisher: Libertas Academica | 2019-04-10, Pages 1179069519836794-1179069519836794
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1177/1179069519836794
• Subjects: Biology, Neuroscience; Biology, Bioinformatics
• Keywords: Galectin; biomarkers; cerebrovascular accident; hemorrhagic stroke; ischemic stroke; transient ischemic attack

Abstract

Due to limitations of neuroimaging, such as the isodense appearance of blood to neuronal tissue in subacute hemorrhagic stroke, a body of studies have been performed to evaluate candidate biomarkers which may aid in accurate determination of cerebrovascular accident type. Beyond aiding in the delineation of stroke cause, biomarkers could also confer useful prognostic information to help clinicians plan use of resources. One of the candidate biomarkers studied for detection of cerebrovascular accident (CVA) includes a class of proteins called galectins. Galectins bind β-galactoside through a highly conserved carbohydrate recognition domain, endowing an ability to interact with carbohydrate moieties on glycoproteins, some of which are relevant to CVA response. Furthermore, galectins-1, -2, -3, -9, and -12 are expressed in tissues relevant to CVA, and some exhibit characteristics (eg, extracellular secretion) that could render feasible their detection in serum. Galectins-1 and -3 appear to have the largest amounts of preclinical evidence, consistently demonstrating increased activity and expression levels during CVA. However, a lack of standardization of biochemical assays across cohort studies limits further translation of these basic science studies. This review aims to increase awareness of the biochemical roles of galectins in CVA, while also highlighting challenges and remaining questions preventing the translation of basic science observations into a clinically useful test.